

IN THE CLAIMS:

Applicants have amended claims 7, 8, 9, 10, 11, 19 and 21 and added new claims 22 to 29. Claims 1 to 6 and 12 to 18 were previously canceled. This listing of claims will replace all prior versions and listings in the application:

Claims 1 to 6 (Canceled).

7. (Currently amended) A marker vaccine, comprising an immunologically effective amount of a mutated bacterium and a pharmaceutically acceptable carrier, said mutated bacterium being selected from the group consisting of the *Salmonella* species *typhimurium*, *enteritidis*, *choleraesuis*, *dublin*, *abortus-ovi*, *abortus-equi*, *derby*, *hadar*, *heidelberg*, *agona*, and *arizonae*, that in its wild type form carries flagella, said mutated bacterium lacking flagellin.

8. (Currently amended) The marker vaccine according to claim 7, wherein the bacteria is in a live attenuated form.

9. (Currently amended) The marker vaccine according to claim 7, wherein the bacteria are inactivated.

10. (Currently amended) The marker vaccine according to claim 7, comprising an adjuvant.

11. (Currently amended) The marker vaccine according to claim 7, in a freeze-dried or spray-dried form.

Claims 12 to 18 (Canceled).

19. (Currently amended) A marker vaccine, comprising an immunologically effective amount of a mutated bacterium and a pharmaceutically acceptable carrier said mutated bacterium

being selected from the group consisting of the *Salmonella* species *typhimurium*, *enteritidis*, *choleraesuis*, *dublin*, *abortus-ovi*, *abortus-equi*, *derby*, *hadar*, *heidelberg*, *agona*, and *arizonae*, that in its wild type form carries flagella, said mutated bacterium lacking at least one antigenic determinant of flagellin or flagella found in its wild type form, and said mutated bacterium being inactivated.

20. (Previously presented) A vaccine for the protection of animals against Salmonellosis strains, comprising:

an immunologically effective amount of a mutated *Salmonella typhimurium* bacterium that in its wild type form carries flagella, said mutated *Salmonella typhimurium* bacterium lacking flagellin, and
a pharmaceutically acceptable carrier.

21. (Currently amended) The vaccine of claim 20, wherein the immunologically effective amount of a mutated *Salmonella typhimurium* bacterium that in its wild type form carries flagella, said mutated *Salmonella typhimurium* bacterium lacking flagellin, comprises an immunologically effective amount of a *Salmonella typhimurium* strain STMP mutated bacterium.

22. (New) An improved *Salmonella* vaccine, having an immunologically effective amount of a *Salmonella* bacterium and a pharmaceutically acceptable carrier, the improvement comprising the *Salmonella* bacterium being a mutated bacterium that in its wild type form carries flagella, but is no longer capable to induce antibodies against at least one antigenic determinant of flagellin or flagella.

23. (New) The improved *Salmonella* vaccine of claim 22, wherein the mutated bacterium is selected from the group consisting of the *Salmonella* species *typhimurium*, *enteritidis*, *choleraesuis*, *dublin*, *abortus-ovi*, *abortus-equi*, *derby*, *hadar*, *heidelberg*, *agona*, and *arizonae*.

24. (New) The improved *Salmonella* vaccine of claim 22, wherein the mutated bacterium lacks flagellin.

25. (New) The improved *Salmonella* vaccine of claim 22, wherein the mutated bacterium is in a live attenuated form.

26. (New) The improved *Salmonella* vaccine of claim 22, wherein the mutated bacterium is inactivated.

27. (New) The improved *Salmonella* vaccine of claim 22, further comprising an adjuvant.

28. (New) The improved *Salmonella* vaccine of claim 22, in a freeze-dried or spray-dried form.

29. (New) A marker vaccine, consisting of:
an immunologically effective amount of a mutated bacterium that in its wild type form carries flagella, said mutated bacterium lacking flagellin and being selected from the group consisting of the *Salmonella* species *typhimurium*, *enteritidis*, *choleraesuis*, *dublin*, *abortus-ovi*, *abortus-equi*, *derby*, *hadar*, *heidelberg*, *agona*, and *arizonae*, and a pharmaceutically acceptable carrier.